CytomX Therapeutics (CTMX) Liabilities and Shareholders Equity (2014 - 2026)

CytomX Therapeutics (CTMX) has 13 years of Liabilities and Shareholders Equity data on file, last reported at $359.4 million in Q1 2026.

• Quarterly Liabilities and Shareholders Equity rose 264.84% year-over-year to $359.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $844.2 million (up 63.22% YoY) and the FY2025 annual result came in at $151.6 million, up 25.75% from the prior year.
• Liabilities and Shareholders Equity grew to $359.4 million in Q1 2026, from $151.6 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $359.4 million in Q1 2026 to a low of $98.5 million in Q1 2025.
• A 5-year average of $203.4 million and a median of $201.8 million in 2023 frame the typical range for Liabilities and Shareholders Equity.
• Annual changes were most pronounced in 2025 — Liabilities and Shareholders Equity sank 46.67% — and 2026, when it jumped 264.84%.
• Tracing CTMX's Liabilities and Shareholders Equity over 5 years: stood at $260.9 million in 2022, then dropped by 22.65% to $201.8 million in 2023, then sank by 40.27% to $120.5 million in 2024, then increased by 25.75% to $151.6 million in 2025, then surged by 137.1% to $359.4 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $359.4 million (Q1 2026), $151.6 million (Q4 2025), and $158.3 million (Q3 2025), per Business Quant data.